Ark Therapeutics, an Anglo-Finnish company announced that its was granted a permission to supply it's gene therapy drug Cerepro to named patients in Finland. Previously the company had obtained a similar approval for named patients in France after a submission by a local neurosurgeon.

Ark is expected to receive MAA decision from EMEA later this year and possibly become a first company to market gene therapy drugs in EU:

http://www.iii.co.uk/investment/detail/?display=news&code=cotn:AKT.L&action=article&articleid=7322960